ITMAT External Advisory Board

Barry Coller, MD (Committee Co-Chair)

Professor | Physician-in-Chief, Vice President for Medical Affairs | The Rockefeller University
Barry S. Coller, M.D., is Vice President for Medical Affairs at The Rockefeller University and physician-in-chief of its hospital. A renowned physician, researcher and medical educator, Dr. Coller is an expert on the basic molecular mechanisms involved in blood clotting and thrombosis. His research accomplishments include the development of a monoclonal antibody to platelets that was developed into the drug abciximab, which is used throughout the world to prevent and treat heart attacks in select patient populations.


Pamela B. Davis, MD, PhD (Committee Co-Chair)

Dean | School of Medicine | Vice President for Medical Affairs | Case Western Reserve University
Pamela B. Davis, M.D., Ph.D. is Dean of the School of Medicine and Vice President for Medical Affairs at Case Western Reserve University in Cleveland OH. She received her AB from Smith College, the Ph.D. and M.D. degrees from Duke, and did residency training at Duke in Internal Medicine, then became a clinical associate at the National Institutes of Health, where she trained in pulmonology. In 1981, she moved to Case Western Reserve University, where she rose through the ranks to become the Arline and Curtis Garvin Research Professor of Pediatrics, Physiology & Biophysics, and Molecular Biology, and to direct the Willard A. Bernbaum Center for Cystic Fibrosis Research. In 2003 she became Vice Dean for Research at the School of Medicine, and in 2006, Interim Dean, and in 2007, Dean. Her research interests are the inflammatory response in the lung of patients with cystic fibrosis, as well as gene transfer approaches to the CF basic defect. Her work has been continuously funded for 30 years by the NIH, and she is now the principal investigator of the University's CTSA. She has received the Paul A. DiSant'Agnese award and the Doris Tulcin Award from the Cystic Fibrosis Foundation, election to the Cleveland Medical Hall of Fame, the Smith College medal, and the Maurice Saltzman Award from the Mt Sinai Health Care Foundation, among other honors, and has steadily been named in "Best Doctors" and "Top Doctors".


Sir Rory Collins, FRCP, FmedSci

Professor of Medicine and Epidemiology | University of Oxford | Principal Investigator and CEO | UK Biobank
In 1985 Sir Rory Collins became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996 he was appointed British Heart Foundation Professor of Medicine and Epidemiology at Oxford. He became Principal Investigator and Chief Executive of the UK Biobank genetic-epidemiology study of 500,000 people in September 2005. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer.


Rebecca Cooke, MBA (Ex Officio)

Vice Dean for Administration and Finance | University of Pennsylvania | Perelman School of Medicine
Rebecca Cooke is the Vice Dean for Administration and Finance for the University of Pennsylvania's Perelman School of Medicine, a position she started in July, 2011. Her responsibilities include Finance; Space and Operations; Research Support Services; Faculty Affairs and Professional Development; Office of Organizational Effectiveness; and Decision Support and Analysis. Prior to arriving at the Perelman School, Rebecca was the Senior Associate Dean for Administration and then the Chief Operating Officer at Northwestern University's Feinberg School of Medicine. The Feinberg School houses undergraduate medical education, PhD programs, and ten graduate and professional programs serving 2,500 students. Rebecca worked closely with the Dean and senior management of the medical school, university and clinical affiliates to plan and implement strategic direction. From 1999 to 2007, Rebecca was the Administrator of the Department of Medicine at the Feinberg School where she was responsible for the administration and financial management of the department's clinical practice, research grants and educational programs. Prior to arriving at Northwestern, Rebecca worked in the Dean's office at Thomas Jefferson University's Jefferson Medical College where she was the Director of Administrative Affairs for the newly formed faculty foundation. Starting in 1989, Rebecca spent six years in departmental administration at the Children's Hospital of Philadelphia, where she worked in Cardiology, Oncology, Gastroenterology, Nephrology and Endocrinology. Rebecca received an MBA in Health Care Administration from the Wharton School of the University of Pennsylvania in 1988 and has a BS in Business Administration from Towson State University.


Daniel J. Drucker, MD

Professor of Medicine | Mount Sinai Hospital | Toronto
Dr. Drucker received his M.D. from the University of Toronto in 1980, and is currently Professor of Medicine. He holds a Canada Research Chair in Regulatory Peptides and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His laboratory is based in the Samuel Lunenfeld Research Institute at Mt. Sinai Hospital in Toronto and studies the molecular biology and physiology of the glucagon-like peptides.


Sir Gordon Duff, MD, PhD, FRCP, FMedSci, FRSE

Gordon is Chairman of the MHRA, the UK regulator of medicines and devices, having previously chaired the Commission on Human Medicines (CHM). He was co-chair of the Cabinet Office's Scientific Advisory Group for Emergencies (SAGE) and the UK Scientific Pandemic Influenza Committee. In 2006, he led the investigation into the disastrous clinical trial of TGN1412, providing safety recommendations for first human exposure to innovative medicines. He was Lord Florey Professor of Molecular Medicine at University of Sheffield (1990-2013), Director of the Division of Genomic Medicine, and Faculty Research Dean. His research interests are in cytokine biology and medicine. He also currently chairs Imperial College's Academic Health Science Centre, and the Academic Health Science Centre of Trinity College, Dublin. In August 2014 he will become Principal of St Hilda's College, Oxford. He was knighted in 2007 for services to the public health.


David Ginsburg, MD

Investigator | Howard Hughes Medical Institute
David Ginsburg is James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, Warner-Lambert/Parke-Davis Professor of Medicine, a member of the Life Sciences Institute at the University of Michigan Medical School, and a Howard Hughes Medical Institute Investigator. He received his B.A. degree in molecular biophysics and biochemistry from Yale University in 1974 and his M.D. degree from Duke University School of Medicine in 1978. His postdoctoral clinical and research training was at the Brigham and Women's Hospital and Children's Hospital, Harvard Medical School. Dr. Ginsburg joined the faculty at the University of Michigan as an Assistant Professor in 1985..

Dr. Ginsburg's laboratory studies the components of the blood-clotting system and how disturbances in their function lead to human bleeding and blood-clotting disorders. The lab has studied the molecular basis of the common disorder von Willebrand disease and is identifying modifier genes that control severity for this and related diseases. The lab has also defined mutations in ADAMTS13, an enzyme that processes von Willebrand factor, as the cause of Thrombotic Thrombocytopenia Purpura. Studies of the bleeding disease combined deficiency of factors V and VIII by the Ginsburg lab identified mutations in a novel pathway for the transport of a select subset of proteins from the ER to the Golgi. Finally, the lab studies the plasminogen activation system, the mechanism by which blood clots are broken down, and has explored the role of this system in a variety of disease processes including atherosclerosis and microbial infection.

Dr. Ginsburg is a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and recipient of the E. Donnall Thomas Lecture and Prize from the American Society of Hematology, the Basic Research Prize and the Distinguished Scientist Award from the American Heart Association, and the 2004 ASCI Award from the American Society of Clinical Investigation. He currently serves on Councils for the National Academy of Sciences and the Institute of Medicine.


Isaac Kohane, MD, PhD

Lawrence J. Henderson Professor of Pediatrics | Harvard Medical School
Isaac Kohane, MD, PhD, co-directs the Center for Biomedical Informatics at Harvard Medical School. He applies computational techniques, whole genome analysis, and functional genomics to study human diseases through the developmental lens, and particularly through the use of animal model systems. Kohane has led the use of whole healthcare systems, notably in the i2b2 project, as "living laboratories" to drive discovery research in disease genomics (with a focus on autism) and pharmacovigilance (including providing evidence for the cardiovascular risk of hypoglycemic agents which ultimately contributed to "black box"ing by the FDA) and comparative effectiveness with software and methods adopted in over 84 academic health centers in the internationally.

Dr. Kohane has published over 200 papers in the medical literature and authored a widely used book on Microarrays for an Integrative Genomics. He has been elected to multiple honor societies including the American Society for Clinical Investigation, the American College of Medical Informatics, and the Institute of Medicine. He leads a doctoral program in genomics and bioinformatics within the Division of Medical Science at Harvard University. He is also an occasionally practicing pediatric endocrinologist.


Steven Nichtberger, MD

Adjunct Professor of Health Management | The Wharton School, University of Pennsylvania
Dr. Nichtberger is a serial entrepreneur with 25 years of healthcare experience focused on developing and commercializing breakthrough medical advances. In addition to leading the capstone course for the Vagelos Life Sciences & Management program at Penn where students form real companies around promising scientific advances while learning about leadership, he has recently focused his investment and company formation efforts on healthcare advances derived from Israeli technologies. He is currently chairman of the board of two recently formed companies. He provides advisory services to investors, biotech companies, and leading academic scientists to maximize the value of breakthrough advances. Previously, Dr. Nichtberger was the head of global marketing for the company at Merck, where he co-chaired the clinical research resource allocation committee. In 2008, he was awarded the prestigious Ernst & Young National Entrepreneur of the Year award for his leadership of a regenerative medicine company. In 1984, Dr. Nichtberger founded the first paperless coupon company, which subsequently licensed core intellectual property to numerous internet coupon providers until 2006. He is a longstanding member of the SAS board of overseers at Penn, past chairman of the board of PA Bio, and a member of the board of governors at Main Line Health.

 


Michelle A. Williams, ScD

Stephen B. Kay Family Professor | Harvard School of Public Health
Michelle A. Williams, ScD is the Stephen B. Kay Family Professor of Public Health and Chair of the Department of Epidemiology at the Harvard School of Public Health. She is also Director of the Health Disparities Research Program of Harvard's Clinical and Translational Science Award (CTSA) Program. Dr. Williams has published over 300 scientific articles; served on several national and international scientific advisory committees; and has received numerous research and teaching awards. Dr. Williams' major research interests include women's reproductive health and child health. Her activities include research with epidemiologists in South America, Asia, and Africa. Her research program focuses on integrating genomic sciences and epidemiological research methods to identify risk factors, diagnostic markers, treatments, and prevention targets for disorders (such as preeclampsia, placental abruption, preterm delivery, and gestational diabetes) that contribute to maternal and infant morbidity and mortality.